Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHD
Part of paid clinical trials in Houston, Texas.
- Sponsor
- M.D. Anderson Cancer Center
- Study ID
- NCT07127926
- Phase
- PHASE1
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Belumosudil — DRUGGiven by PO
Study Details
The primary objective of the study is to evaluate belumosudil pharmacokinetics of whole tablets and crushed tablets suspended in water in patients suffering from chronic graft-versus-host disease (cGVHD).
Key Dates
- First listed
- Aug 17, 2025
- Start date
- Feb 9, 2026
- Status verified
- Aug 2026
- Primary completion
- Dec 31, 2027
- Completion
- Dec 31, 2027
Study Design
- Enrollment
- 8 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Experimental: BelumosudilOn Days 0 to 7, you will: • Take whole belumosudil tablet by mouth 1 time a day at same time of the day. On Day 7, you will then have your 1st pharmacokinetic visit at MD Anderson: • Blood samples (about 1 teaspoon) will be collected before dosing, and 0.5, 1, 2, 4, 8, 12, and 24 hours after belumosudil dosing. On Days 8 to 14, you will: • Take crushed belumosudil tablet by mouth 1 time a day at same time of the day. On Day 14, you will then have your 2nd pharmacokinetic visit to MD Anderson: • Blood samples (about 1 teaspoon) will be collected before dosing, and 0.5, 1, 2, 4, 8, 12, and 24 hours after belumosudil dosing.
Primary Outcome Measure
Safety and adverse events (AEs [ Time Frame: Through study completion; an average of 1 year ]
Central Contacts
- Amin Alousi, MD(713) 745-8613
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| The University of Texas M. D. Anderson Cancer Center | Houston | Texas | 77030 | Amin Alousi, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Houston, TX
Related Studies
- A Long-term Extension Study of PCI-32765 (Ibrutinib)PHASE3 · Recruiting · Janssen Research & Development, LLC · Orange, California
- A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)PHASE2 · Recruiting · Sanofi · Los Angeles, California
- BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)PHASE2 · Recruiting · Dana-Farber Cancer Institute · Stanford, California
- Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host DiseasePHASE2 · Recruiting · Fred Hutchinson Cancer Center · Duarte, California